Influenza Clinical Trial
Official title:
Characterization of Innate Immune Responses to AS03 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine
Background:
- Adjuvants are substances included in vaccines that stimulate the immune system and increase
the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in
Europe. However, it has not been fully tested in the United States. Researchers want to test
the immune responses of people who receive a bird flu vaccine with or without AS03 to better
understand how the adjuvant works. This information may help develop better flu vaccines.
Objectives:
- To compare the healthy immune system responses to bird flu vaccine with or without the AS03
adjuvant.
Eligibility:
- Healthy volunteers between 18 and 45 years of age.
Design:
- Participants will be screened with a physical exam and medical history.
- Participants will be assigned to one of two groups. Each group will have an initial
vaccine, followed by a booster vaccine 21 days later. Both vaccinations will use the
same type of vaccine. One group will have the vaccine with AS03; the other group will
have the vaccine without it.
- All participants will have two 36-hour inpatient stays to receive the vaccine. Each stay
will involve the vaccination, followed by regular and frequent blood draws. Participants
will be monitored for any signs or symptoms that may be caused by the vaccine.
- Additional blood samples will be collected 7, 28, 42, and 100 days after the initial
vaccination.
Adjuvants have been in use for many decades to enhance the effects of vaccines on the host
immune system, yet we know very little on how they actually work. Better understanding of the
mechanism by which adjuvants activate the immune system will enable us to develop better and
safer vaccines as well as a broad range of immune interventions to a wide spectrum of
diseases including cancer and autoimmunity.
In the current study we propose to study the effect of AS03 adjuvant on the innate/early
immune response to H5N1, avian flu, a potentially lethal disease that most subjects are
assumed to be naive to AS03 is an adjuvant oil in water emulsion containing
DL-alpha-tocopherol, squalene and the non-ionic detergent Tween 80 that has been widely used
as an adjuvant to flu vaccines produced by GlaxoSmithKline(GSK).
We therefore propose to randomize up to 60 healthy volunteers into two intervention arms (25
volunteers in each arm with up to 10 total replacements in the event a volunteer does not
return for the first vaccine). The first arm will receive a vaccine containing H5N1 with AS03
adjuvant, the second arm will receive H5N1 without AS03 adjuvant. Both arms will receive
primary and booster vaccination followed by repeated blood sampling to evaluate the immune
responses. We will apply high throughput analytic techniques and use systems biology methods
to integrate the collected data and draw a description of the immune system response with and
without the adjuvant.
The primary objective is to compare multiplex immune response signatures following two
(primary and a boost) vaccinations with the GSK AS03 adjuvanted H5N1 influenza vaccine, or
the non-adjuvanted form of the H5N1 influenza vaccine, at the 3.75 mcg dose and given 21 days
apart and identify differences in very early innate immune responses. These immune signatures
will also be correlated with the clinical observations especially safety related local and
systemic events.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |